Dose Ranging Study of Pazopanib to Treat Neovascular Age-Related Macular Degeneration
Public ClinicalTrials.gov record NCT01134055. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
MD7110852, A Phase 2b Dose-Ranging Study of Pazopanib Eye Drops Versus Ranibizumab Intravitreal Injections for the Treatment of Neovascular Age-Related Macular Degeneration
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to determine the safety and efficacy of different dosage regimens of pazopanib eye drops for the treatment of neovascular age-related macular degeneration.
Study identification
- NCT ID
- NCT01134055
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 510 participants
Conditions and interventions
Conditions
Interventions
- pazopanib eye drops Drug
- placebo Drug
- ranibizumab intravitreal injection Biological
Drug · Biological
Eligibility (public fields only)
- Age range
- 50 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 1, 2010 (Actual)
- Primary completion
- Oct 1, 2012 (Actual)
- Completion
- Oct 1, 2012 (Actual)
- Last update posted
- Jan 8, 2018
2010 – 2012
United States locations
- U.S. sites
- 37
- U.S. states
- 19
- U.S. cities
- 34
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| GSK Investigational Site | Peoria | Arizona | 85381 | — |
| GSK Investigational Site | Phoenix | Arizona | 85014 | — |
| GSK Investigational Site | Phoenix | Arizona | 85020 | — |
| GSK Investigational Site | Tucson | Arizona | 85704 | — |
| GSK Investigational Site | Tucson | Arizona | 85710 | — |
| GSK Investigational Site | Irvine | California | 92697 | — |
| GSK Investigational Site | Loma Linda | California | 92354 | — |
| GSK Investigational Site | Poway | California | 92064 | — |
| GSK Investigational Site | Santa Ana | California | 92705 | — |
| GSK Investigational Site | Golden | Colorado | 80401 | — |
| GSK Investigational Site | Fort Myers | Florida | 33901 | — |
| GSK Investigational Site | Winter Haven | Florida | 33880 | — |
| GSK Investigational Site | Chicago | Illinois | 60612 | — |
| GSK Investigational Site | Leawood | Kansas | 66211 | — |
| GSK Investigational Site | Paducah | Kentucky | 42001 | — |
| GSK Investigational Site | Baltimore | Maryland | 21287 | — |
| GSK Investigational Site | Boston | Massachusetts | 02114 | — |
| GSK Investigational Site | Royal Oak | Michigan | 48073 | — |
| GSK Investigational Site | Traverse City | Michigan | 49686 | — |
| GSK Investigational Site | New York | New York | 10003 | — |
| GSK Investigational Site | Asheville | North Carolina | 28803 | — |
| GSK Investigational Site | Chapel Hill | North Carolina | 27599 | — |
| GSK Investigational Site | Charlotte | North Carolina | 28210 | — |
| GSK Investigational Site | Beachwood | Ohio | 44122 | — |
| GSK Investigational Site | Cleveland | Ohio | 44130 | — |
| GSK Investigational Site | Cleveland | Ohio | 44195 | — |
| GSK Investigational Site | Columbus | Ohio | 43212 | — |
| GSK Investigational Site | Ashland | Oregon | 97520 | — |
| GSK Investigational Site | Portland | Oregon | 97239 | — |
| GSK Investigational Site | Philadelphia | Pennsylvania | 19107 | — |
| GSK Investigational Site | Austin | Texas | 78705 | — |
| GSK Investigational Site | Dallas | Texas | 75231 | — |
| GSK Investigational Site | Fort Worth | Texas | 76104 | — |
| GSK Investigational Site | Salt Lake City | Utah | 84107 | — |
| GSK Investigational Site | Seattle | Washington | 98104 | — |
| GSK Investigational Site | Silverdale | Washington | 98383 | — |
| GSK Investigational Site | Madison | Wisconsin | 53705 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 40 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01134055, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 8, 2018 · Synced Oct 29, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT01134055 live on ClinicalTrials.gov.